precision medicine tagged posts

Researchers at Columbia University College of Dental Medicine have developed an exosome-based platform, “safeEXO-Cas,” that significantly enhances the delivery of CRISPR/Cas9 genome editing components to specific cells and tissues.

CRISPR/Cas9 is a unique technology that enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence. The study, published in Theranostics, demonstrates the potential of this innovative platform to revolutionize gene therapy and precision medicine.

The research, led by Dr...

Raw image data collected from dGEMRIC MRI protocol at an inversion time of 1600 milliseconds (left). The T1 map computed from seven different inversion times using the automated, real-time, quantitative magnetic resonance imaging pipeline (right). Credit: Image courtesy of University of Texas at Austin, Texas Advanced Computing Center

A new, automated platform that returns in-depth analyses of MRI scans in minutes, rather than hours or days has been developed by Texas Advanced Computing Center (TACC), University of Texas Health Science Center (UTHSC) and Philips Healthcare. The system has the potential to minimize patient callbacks, save millions annually, and advance precision medicine.

The team presented a proof-of-concept demonstration of the platform at the International Conference on ...

UCH-L3

Researchers at Mayo Clinic have identified an enzyme called UCHL3 that regulates the BRCA2 pathway, which is important for DNA repair. Results of this research are published online in Genes & Development. “DNA repair is a fundamental mechanism to prevent the accumulation of mutations in DNA and human disease,” says Zhenkun Lou, Ph.D., a molecular pharmacologist at Mayo Clinic.

“The BRCA2 pathway is important for DNA repair, and mutation of the BRCA2 gene is linked to increased cancer risk, especially breast cancer and ovarian cancer.” Dr. Lou says UCHL3 is highly expressed in some cancers, and mutated or deleted in other cancers. Cancer cells with high UCHL3 expression are resistant to chemotherapy; whereas, cancer cells with low UCHL3 are more sensitive to chemotherapy...